Jack Bendheim Sells 6,772 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 6,772 shares of Phibro Animal Health stock in a transaction dated Thursday, January 29th. The stock was sold at an average price of $40.12, for a total value of $271,692.64. Following the sale, the chief executive officer owned 38,673 shares of the company’s stock, valued at approximately $1,551,560.76. This represents a 14.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Jack Bendheim also recently made the following trade(s):

• On Friday, January 30th, Jack Bendheim sold 6,693 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total transaction of $268,322.37.
• On Friday, January 23rd, Jack Bendheim sold 1,235 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.55, for a total transaction of $50,079.25.
• On Thursday, January 22nd, Jack Bendheim sold 13,158 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.98, for a total transaction of $552,372.84.
• On Wednesday, January 21st, Jack Bendheim sold 14,687 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.68, for a total transaction of $612,154.16.
• On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.02, for a total transaction of $117,338.64.
• On Wednesday, January 14th, Jack Bendheim sold 3,651 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.53, for a total transaction of $147,975.03.
• On Tuesday, January 13th, Jack Bendheim sold 7,551 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.32, for a total transaction of $304,456.32.
• On Friday, January 9th, Jack Bendheim sold 213 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.16, for a total value of $8,554.08.
• On Wednesday, January 7th, Jack Bendheim sold 328 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.09, for a total value of $13,149.52.
• On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.93, for a total value of $235,429.36.

Phibro Animal Health Stock Performance

Phibro Animal Health stock opened at $41.31 on Wednesday. The stock has a fifty day moving average price of $39.79 and a 200 day moving average price of $38.04. Phibro Animal Health Corporation has a 52 week low of $16.16 and a 52 week high of $46.42. The firm has a market capitalization of $1.67 billion, a P/E ratio of 24.89, a PEG ratio of 1.19 and a beta of 0.80. The company has a current ratio of 3.09, a quick ratio of 1.35 and a debt-to-equity ratio of 2.32.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.15. Phibro Animal Health had a return on equity of 36.26% and a net margin of 4.85%.The firm had revenue of $363.89 million for the quarter, compared to analyst estimates of $345.44 million. Equities research analysts anticipate that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently issued reports on PAHC shares. Weiss Ratings reissued a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. JPMorgan Chase & Co. boosted their price target on Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Finally, Zacks Research upgraded Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Phibro Animal Health has an average rating of “Hold” and an average price target of $31.40.

Institutional Investors Weigh In On Phibro Animal Health

A number of large investors have recently modified their holdings of PAHC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Phibro Animal Health by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock worth $260,000 after acquiring an additional 546 shares in the last quarter. Millennium Management LLC raised its stake in shares of Phibro Animal Health by 74.3% during the first quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock valued at $7,733,000 after purchasing an additional 154,281 shares during the period. Jane Street Group LLC raised its stake in shares of Phibro Animal Health by 65.3% during the first quarter. Jane Street Group LLC now owns 33,917 shares of the company’s stock valued at $724,000 after purchasing an additional 13,404 shares during the period. State of Alaska Department of Revenue lifted its position in shares of Phibro Animal Health by 7.6% during the second quarter. State of Alaska Department of Revenue now owns 12,129 shares of the company’s stock worth $309,000 after purchasing an additional 859 shares in the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its stake in shares of Phibro Animal Health by 10.0% in the second quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 11,530 shares of the company’s stock valued at $294,000 after purchasing an additional 1,044 shares during the period. Institutional investors and hedge funds own 99.34% of the company’s stock.

Key Headlines Impacting Phibro Animal Health

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Board declared a quarterly cash dividend of $0.12 per share payable March 25, 2026 (record date March 4). Dividend supports shareholder returns and can attract income-minded investors. Phibro Animal Health Corporation Declares Quarterly Dividend
• Positive Sentiment: Zacks Research reiterated a Strong-Buy and nudged several forward-year and quarterly EPS estimates higher (FY2027/FY2028 upgrades and Q4/Q2 tweaks), signaling improved analyst sentiment about medium-term earnings power. 4 Medical Product Stocks to Watch From a Challenging Industry (Revised)
• Positive Sentiment: Institutional buying earlier (new positions reported from Capricorn Fund Managers, Allspring Global, Squarepoint and others) indicates continued interest from funds and helps support the stock’s valuation multiple. MarketBeat PAHC Profile
• Neutral Sentiment: Industry coverage pieces name PAHC among medical/animal-health names to watch amid steady demand despite macro headwinds — a constructive backdrop but not an immediate catalyst. 4 Medical Product Stocks to Watch From a Challenging Industry
• Negative Sentiment: CEO Jack Bendheim has executed a sequence of insider sales in January (recent disclosed sales include ~6,693 shares at ~$40.09), which investors often interpret as a sign of insider cashing out and can pressure sentiment. Phibro Animal Health CEO Jack Bendheim Sells Shares
• Negative Sentiment: Mixed analyst tweaks include a small near-term cut (Zacks trimmed Q2 2026 EPS modestly), which could feed short-term selling or cautious guidance expectations despite longer-term upgrades. (See Zacks notes above.)

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.